http://www.advfn.com/nasdaq/rss.asp?symbol=VRTX Vertex Pharmaceuticals Incorporated Company Newsfeed en Wed, 01 May 2013 08:57:32 EDT Wed, 01 May 2013 08:57:32 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=57393753&headline=u-s-hot-stock-futures-hot-stocks-to-watch http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=57393753&headline=u-s-hot-stock-futures-hot-stocks-to-watch <div class='newsbody'><p> Among the companies with shares expected to actively trade in Wednesday's session are Trulia Inc.(TRLA), SPX Corp. (SPW) and DreamWorks Animation SKG Inc. (DWA). </p> <p> Trulia's first-quarter loss narrowed as the online real-estate-listing service's revenue nearly doubled... Wed, 01 May 2013 08:57:32 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=57384936&headline=vertex-pharmaceuticals-swings-to-1st-quarter-loss-on-write-down http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=57384936&headline=vertex-pharmaceuticals-swings-to-1st-quarter-loss-on-write-down <div class='newsbody'><pre> By Debbie Cai </pre> <p> Vertex Pharmaceuticals Inc. (VRTX) swung to a first-quarter loss on a write-down tied to its hepatitis C program, as sales of Incivek also slid. </p> <p> The pharmaceutical company has now reported four straight quarters of losses amid slumping sales... Tue, 30 Apr 2013 17:02:11 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=57295705&headline=fda-gives-breakthrough-designation-to-merck-skin-cancer-drug http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=57295705&headline=fda-gives-breakthrough-designation-to-merck-skin-cancer-drug <div class='newsbody'><pre> By Peter Loftus </pre> <p> An experimental Merck &amp; Co. (MRK) skin-cancer drug has been designated as a "breakthrough therapy" by the U.S. Food and Drug Administration, which could ease the treatment's path to market. </p> <p> The drug, lambrolizumab, showed promise in... Tue, 23 Apr 2013 21:30:42 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=57044713&headline=vertex-signs-deal-with-bristol-myers-for-hepatitis-c-treatment http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=57044713&headline=vertex-signs-deal-with-bristol-myers-for-hepatitis-c-treatment <div class='newsbody'><pre> By Saabira Chaudhuri </pre> <p> Vertex Pharmaceuticals Inc. (VRTX) entered a nonexclusive agreement with Bristol-Myers Squibb Co. (BMY) to conduct midstage studies for hepatitis C treatments, its latest collaboration as part of its push to develop treatments for the liver... Fri, 05 Apr 2013 08:59:12 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=56564103&headline=rise-of-generics-specialty-drugs-prompt-shift-in-drug-spending http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=56564103&headline=rise-of-generics-specialty-drugs-prompt-shift-in-drug-spending <div class='newsbody'><pre> By Jon Kamp and Peter Loftus </pre> <p> U.S. spending on basic prescription drugs like cholesterol-lowering pills recorded a rare decline last year under pressure from generics, but spending on more complicated drugs continued to soar, raising challenges for health-care payers... Tue, 05 Mar 2013 00:31:11 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=55539250&headline=correction-to-vertexs-fda-warning-story http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=55539250&headline=correction-to-vertexs-fda-warning-story <div class='newsbody'><p> "Vertex's Hepatitis C Drug Receives Another Blow With FDA Warning" published at 4:39 p.m. ET incorrectly said the new warning instructs patients to discontinue their use of the drug if a severe rash occurs. The warning to discontinue use existed on the previous label, but the... Wed, 19 Dec 2012 17:36:09 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=55538720&headline=vertexs-hepatitis-c-drug-receives-another-blow-with-fda-warning http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=55538720&headline=vertexs-hepatitis-c-drug-receives-another-blow-with-fda-warning <div class='newsbody'><pre> By Joseph Walker </pre> <p> The Food and Drug Administration on Wednesday placed a new label on Vertex Pharmaceuticals Inc.'s (VRTX) hepatitis C drug Incivek, warning patients that the drug has caused fatal skin rashes in some patients. </p> <p> Two patients died after developing... Wed, 19 Dec 2012 17:09:22 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=55330943&headline=fda-approves-highest-number-of-new-drugs-since-2004 http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=55330943&headline=fda-approves-highest-number-of-new-drugs-since-2004 <div class='newsbody'><pre> By Jennifer Corbett Dooren </pre> <p> WASHINGTON--The U.S. Food and Drug Administration has approved the most new drugs in eight years--partly reflecting improvements by the pharmaceutical industry in moving experimental drugs out of company pipelines. </p> <p> Through the... Wed, 05 Dec 2012 15:02:25 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=54996120&headline=gilead-sciences-still-seen-as-frontrunner-in-hepatitis-c-drug http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=54996120&headline=gilead-sciences-still-seen-as-frontrunner-in-hepatitis-c-drug <div class='newsbody'><pre> By Joseph Walker </pre> <p> Gilead Sciences Inc. (GILD) solidified its position as the frontrunner in a race to develop a new pill-based drug for hepatitis C, a deadly liver virus affecting 180 million people world-wide. </p> <p> Abbott Laboratories (ABT) and Bristol-Myers... Tue, 13 Nov 2012 12:43:14 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=54832765&headline=vertex-shares-fall-as-worries-over-growth-prospects-rise http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=54832765&headline=vertex-shares-fall-as-worries-over-growth-prospects-rise <div class='newsbody'><pre> By Joseph Walker </pre> <p> Vertex Pharmaceuticals Inc's (VRTX) shares fell as much as 17% Friday after disappointing third-quarter sales of its hepatitis C and cystic fibrosis treatments raised concerns about the company's growth prospects in those key markets. </p> <p> The... Fri, 02 Nov 2012 14:31:07 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=54731514&headline=correction-to-2nd-update-on-companies-postponing-earnings-reports http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=54731514&headline=correction-to-2nd-update-on-companies-postponing-earnings-reports <div class='newsbody'><p> "2nd UPDATE: Companies Postpone Earnings Reports in Light of Hurricane Sandy," at 12:04 p.m. EDT, used the incorrect name in the sixth-to-last paragraph for one of the companies that said they intend to report results as planned Tuesday morning. The company is TRW Automotive... Mon, 29 Oct 2012 14:50:35 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=54517491&headline=abbott-hepatitis-c-regimen-suppresses-virus-in-new-study http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=54517491&headline=abbott-hepatitis-c-regimen-suppresses-virus-in-new-study <div class='newsbody'><pre> By Peter Loftus </pre> <p> An experimental all-oral drug regimen developed by Abbott Laboratories (ABT) suppressed the hepatitis C virus in most patients in a new clinical trial. </p> <p> The results helped guide Abbott to decide on a regimen based on three experimental drugs... Mon, 15 Oct 2012 10:29:47 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=54393387&headline=mid-cap-stocks-slide-monday-tied-to-big-etf-trades-traders http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=54393387&headline=mid-cap-stocks-slide-monday-tied-to-big-etf-trades-traders <div class='newsbody'><pre> By Matt Jarzemsky and Chris Dieterich </pre> <p> When midsize stocks retreated as their large and small counterparts rose Monday, traders scratched their heads about the unusual activity. The culprit, traders later surmised, was heavy selling in two exchange-traded funds--and... Wed, 03 Oct 2012 12:15:04 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=52682993&headline=elliott-third-point-funds-drop-in-may-largest-drop-for-elliott http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=52682993&headline=elliott-third-point-funds-drop-in-may-largest-drop-for-elliott <div class='newsbody'><pre> By Amy Or </pre> <p> NEW YORK--Two of the hedge-fund industry's most widely watched managers posted a down month in May, with Paul Singer's Elliott Management recording the largest monthly decline since November 2008 in one of its main funds. </p> <p> Its $13 billion Elliott... Wed, 06 Jun 2012 18:26:10 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=52603318&headline=wsj-blog-health-am-vitals-fda-warns-of-fake-adderall http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=52603318&headline=wsj-blog-health-am-vitals-fda-warns-of-fake-adderall <div class='newsbody'><p> (This story has been posted on The Wall Street Journal Online's Health Blog at http://blogs.wsj.com/health.) </p> <p> By Robert Lee Hotz </p> <p> Here is what's making health news: </p> <p> FDA Warns About Fakes of ADHD Drug Adderall (WSJ): A counterfeit version of Teva Pharmaceutical... Wed, 30 May 2012 08:25:25 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=52587766&headline=us-hot-stock-futures-hot-stocks-to-watch http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=52587766&headline=us-hot-stock-futures-hot-stocks-to-watch <div class='newsbody'><p> Among the companies with shares expected to actively trade in Tuesday's session are Chesapeake Energy Corp. (CHK), LeCroy Corp. (LCRY) and Vertex Pharmaceutical Inc. (VRTX). </p> <p> Activist investor Carl Icahn reported a 7.6% stake in Chesapeake Energy on Friday and called... Tue, 29 May 2012 09:15:58 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=51907164&headline=correct-abbott-drugs-suppress-hepatitis-c-virus-in-2-mid-stage http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=51907164&headline=correct-abbott-drugs-suppress-hepatitis-c-virus-in-2-mid-stage <div class='newsbody'><p> ("Abbott Drugs Suppress Hepatitis C Virus In 2 Mid-Stage Studies" published at 10:07 a.m. EDT incorrectly described Abbott's role in developing the drug ABT-450. A corrected version follows.) </p> <pre> By Peter Loftus Of DOW JONES NEWSWIRES </pre> <p> Experimental drugs from... Wed, 04 Apr 2012 15:25:35 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=51902826&headline=abbott-drugs-suppress-hepatitis-c-virus-in-2-mid-stage-studies http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=51902826&headline=abbott-drugs-suppress-hepatitis-c-virus-in-2-mid-stage-studies <div class='newsbody'><pre> By Peter Loftus Of DOW JONES NEWSWIRES </pre> <p> Experimental drugs from Abbott Laboratories (ABT) suppressed the hepatitis C virus in most patients in two small, mid-stage studies. </p> <p> The results unveiled Wednesday could reinforce Abbott's position as a key player... Wed, 04 Apr 2012 10:38:34 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=50695788&headline=merck-will-consider-deals-to-expand-hepatitis-c-drug-lineup http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=50695788&headline=merck-will-consider-deals-to-expand-hepatitis-c-drug-lineup <div class='newsbody'><pre> By Peter Loftus Of DOW JONES NEWSWIRES </pre> <p> SAN FRANCISCO -(Dow Jones)- Merck &amp; Co. (MRK) will consider making acquisitions as part of its strategy to develop the next generation of hepatitis C treatments, the drug maker's research chief said Tuesday. </p> <p> The... Tue, 10 Jan 2012 20:28:12 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=50540780&headline=tip-sheet-fidelity-manager-sees-opportunity-in-biotech-funding http://www.advfn.com/nasdaq/StockNews.asp?stocknews=VRTX&article=50540780&headline=tip-sheet-fidelity-manager-sees-opportunity-in-biotech-funding <div class='newsbody'><p> (This article was originally published Thursday.) </p> <pre> </pre> <p> --Fidelity fund searches for biotech stocks with cheaper valuations </p> <p> --Funding crunch has led to biotech-sector shakeout </p> <p> --Portfolio manager says science continues to advance despite financial... Sat, 24 Dec 2011 18:15:19 EST